ALNY stock gains after submitting a regulatory application in the EU, seeking the approval of vutrisiran to treat ATTR ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced the submission of a Type II Variation to the European Medicines Agency (EMA) for ...

Vutrisiran is also in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), which encompasses both wild-type and hereditary forms of the disease. Alnylam (Nasdaq ...

Alnylam Pharmaceuticals ... an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). Vutrisiran is the generic name for AMVUTTRA ...

Vutrisiran is also in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), which encompasses both wild-type and hereditary forms of the disease. Alnylam (Nasdaq: ALNY) has ...

Alnylam Pharmaceuticals (ALNY) announced the submission of a Type II Variation to the European Medicines Agency for vutrisiran, an ...

Please note that Alnylam already markets vutrisiran in the EU under the brand name Amvuttra for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or ...

The firm's confidence is anchored in the anticipated successful launch of AMVUTTRA for treating ATTR amyloidosis with cardiomyopathy (ATTR-CM) in the second half of 2025. Alnylam's recent TTR ...

Alnylam Pharmaceuticals ... a drug aimed at treating ATTR amyloidosis with cardiomyopathy (ATTR-CM). The submission is based on the positive outcome of the HELIOS-B Phase 3 study, which showed ...